• Home
  • Products & Services
    • VBS Pharmaceuticals
      • CAR Peptide Technology
      • CAR Peptide Applications
        • Co-administered Therapeutics
        • Pulmonary Hypertension
        • Sepsis
        • Gene Therapy
    • VBS Interventional
      • Interventional Technology
        • Endoarterial Biopsy Catheter
        • Endoarterial Biopsy Procedure
        • Endoarterial Biopsy Sequence
        • Endoarterial Biopsy Sample
        • Single Use Components
        • Endoarterial Biopsy Kit
      • Interventional Applications
        • Pulmonary Arterial Hypertension
        • Peripheral Vascular Disease
        • Lung Transplant Rejection
        • Vasculitis/Collagen Vascular Disease
        • Coronary Artery Disease
        • Critical Care Applications — Acute Lung Injury & Acute Respiratory Distress Syndrome
        • Lung Cancer
    • VBS Molecular Diagnostics
      • Molecular Diagnostics Technology
  • Product Pipeline
  • COVID-19
  • News
  • About VBS
    • VBS Team
    • VBS Board of Directors
  • VBS Scientific Articles
  • Investment
  • Contact

Investment page

VBS is currently seeking corporate partners, strategic investors, and accredited investors interested in sharing in the financial benefits to be accrued from the successful development of our products and services. Investment drives innovation of cutting edge technologies and increases our ability to provide much sought-after solutions for some of the most serious disease challenges in medicine today.

If you are interested in finding out more about investment opportunities at VBS please email us at: investment@vascularbiosciences.com

Latest News

  • Vascular BioSciences Receives STTR Fast-Track Grant for CAR Liposomes with VA Hospital of Northern California
  • Vascular BioSciences Announces New Preclinical Research Results Demonstrating Improved Pulmonary Hypertension and Sepsis Survival with CAR Peptide
  • FDA Grants Vascular BioSciences Humanitarian Use Device (HUD) Designation to the Endoarterial Biopsy Catheter for Group 1 Pulmonary Arterial Hypertension
  • Vascular BioSciences Presented Results of CAR Peptide Targeted Augmentation of Chronic Prostanoid Treatment in PAH at the ATS Meeting in Dallas, Texas
  • Vascular BioSciences Awarded $2 Million Phase II STTR Grant From NHLBI to Develop CAR Peptide as a Targeted Therapy for Pulmonary Hypertension

Contact Us

For inquiries about investment in VBS, please contact us at investment@vascularbiosciences.com

  • Home
  • Products & Services
  • Product Pipeline
  • News
  • About VBS
  • VBS Scientific Articles
  • Investment
  • Contact Info
  • Privacy Policy